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excessive handling of a flammable liquid, i.e., diethyl ether.
The work-up involves the following steps:
The reaction mixture is quenched into ice water;
An aqueous saturated ammonium chloride solution IS
added;
The mixture is extracted with diethyl ether;
The ether phase is then extracted with 20% aqueous acetic
acid;
The acid phase is made alkaline with 10 N aqueous
sodium hydroxide;
The aqueous phase is extracted with diethyl ether (2x);
The combined ethereal extracts are dried over anhydrous
~C03;
The ether extract is treated with activated carbon; and
The solvent is evaporated in vacuum to give Br-Diol, an
oil.
The above work-up process is very laborious and is not
suited for large-scale production. Again, it involves the
20 excessive handling of flammable solvents, such as diethyl
ether, and it involves numerous unit operations, thereby
reducing productivity. Moreover, it is noted that Br-Diol is
isolated as the free amine and is an oil. The physical
characteristics of Br-Diol are important. Since Br-Diol is an
25 oil, it cannot be isolated as a crystalline solid and, thus, it
cannot be purified by techniques such as crystallization/
recrystallization. Purification of this oil by crystallization or
similar techniques is not described. It is believed that this is
one of the major reasons why the process described in U.S.
30 Pat. No. 4,136,193 fails to provide Citalopram in the quality,
i.e., purity, required for drug applications. In addition, in
order to meet the tight specifications for Citalopram, it is
critical that purity is established at this stage.
In step three, Br-Diol is subjected to a ring closure
35
reaction with 60% aqueous phosphoric acid. In a typical
reaction, 5-bromophthalide is heated with excess (30
equivalents) 60% aqueous phosphoric acid for 3 h and then
neutralized with saturated aqueous ammonia. The resulting
mixture is then extracted with diethyl ether, and the ether
40 extract is dried over potassium carbonate. The ether extract
is then treated with activated charcoal and stripped of
solvent under reduced pressure to give the compound of
Formula IV ("5-Br").
As mentioned above, step three employs a large excess of
45 60% aqueous phosphoric acid. This is troublesome because
on reaction completion excess phosphoric acid has to be
neutralized with ammonia. Neutralization is an extremely
exothermic process and heat management becomes a major
issue in the commercial-scale production of this material. In
50
addition, the use of such a large excess of phosphoric acid
increases the cost of commercial scale operations due to the
use of excess reagents, longer cycle times and reduced
loading. Moreover, from a safety point of view, the use of
flammable solvents, such as diethyl ether, is discouraged for
55 the commercial-scale production of organic compounds.
In step four, 5-Br is reacted with cuprous cyanide in DMF
to give, after the work-up, Citalopram. The reaction condi-
tions and work-up for the process described in U.S. Pat. No.
4,136,193 is as follows:
60 5-Br is reacted with CuCN in DMF at reflux for 4 h;
The reaction mixture is cooled to 55° C. and quenched
into an aqueous solution of ethylene diamine;
The oily layer is separated and the aqueous layer is
extracted with benzene;
The combined organic phases are washed with 10%
aqueous sodium cyanide;
CH3/
(CHzhN ·HBr
\
CH3
F
NC
CROSS-REFERENCE TO RELATED
APPLICATION
BACKGROUND OF THE INVENTION
1
PROCESS FOR THE PREPARATION OF
CITALOPRAM INTERMEDIATE
The present application claims priority to U.S. Provisional
Patent Application No. 60/324,821, filed Sep. 24, 2001, the
teachings of which are incorporated herein by reference for
all purposes.
Citalopram is an antidepressant drug that is widely used
in both the United States and Europe. Its mode of action and
activity have been described in various publications. The 15
active ingredient is an HBr or oxalate salt, preferably an HBr
salt. Citalopram has the following structure:
Several processes have been described in the literature for
preparing Citalopram (see, Drugs of Future, 25(6):620
(2000). Citalopram was first disclosed in German Patent
2,657,271, which is the German equivalent of now expired
U.S. Pat. No. 4,136,193. In this patent, 5-bromophthalide
(5-BP) was converted via a five-step reaction sequence to
Citalopram. This route for preparing Citalopram is depicted
in FIG. 1, and constitutes the basis of several patents and
patent applications.
Attempts to reproduce the process described in U.S. Pat.
No. 4,136,193 for the preparation of Citalopram in the
quality specifications required for its use in pharmaceutical
applications have been unsuccessful. It is noted that the
quality specifications for pharmaceutical quality Citalopram
are extremely stringent and require material with purity in
excess of 99.7%. Difficulty encountered in manufacturing
Citalopram of the required purity by the process described in
German Patent No. 2,657,013, U.S. Pat. No. 4,136,193 and
PCT International Publication Nos. WO 00/11926 and WO
00/13648 was recently described by Lundbeck in WO
01/45483 A2 (see, page 2, line 26).
Following is the detailed description of the process
described in U.S. Pat. No. 4,136,193. It is noted that the
experimental process described in U.S. Pat. No. 4,136,193 is
for the 4-chlorophenyl analog, but it is noted therein that the
process is applicable to the 4-fluorophenyl derivative as
well. As illustrated in FIG. 1, the process described in U.S.
Pat. No. 4,136,193 involves a 5-step conversion of
5-bromophthalide to Citalopram.
In the first step, a compound of Formula I ("5-BP") is
reacted with p-fluorophenyl-magnesium halide; in the sec-
ond step, the intermediate of a compound of Formula II is
isolated and reacted with N,N-
dimethylaminopropylmagnesium halide to give the diol of
Formula III ("Br-Diol"). The Grignard reaction is conducted 65
in traditional solvents, such as diethyl ether and THE
Unfortunately, the work-up is very complex and involves
US 6,967,259 B2
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The organic layer is dried, treated with activated carbon,
and concentrated under vacuum to give an oil;
The oil is dissolved in ether and extracted with aqueous
acetic acid;
The acetic acid layer is made alkaline with 10 N aqueous 5
sodium hydroxide and extracted with ether; and
The ethereal extract is dried over K2 C03 , treated with
activated charcoal, and stripped of solvent to give
Citalopram.
Unfortunately, there are numerous problems with step 10
four. First, the reaction does not go to completion in 4 h; in
reality, conversion after 4 h is <10%. Removal of unreacted
5-Br is difficult and normal purification techniques, such as
extraction, crystallization, etc., are not effective. When the
reaction is pushed to achieve higher conversion, formation 15
of numerous unidentified side-products is observed. In short,
the process described in U.S. Pat. No. 4,136,193 does not
work to provide acceptable quality Citalopram. Moreover,
the work-up is laborious and involves the use of undesirable
solvents such as benzene and diethyl ether. 20
In the fifth and final step of the process described in U.S.
Pat. No. 4,136,193, Citalopram is converted to Citalopram-
.HBr or the oxalate salt in the conventional manner-a
process is not described for this conversion.
Another route for the preparation of Citalopram has been 25
described in U.S. Pat. No. 4,650,884. This process is based
on 5-cyanophthalide (,,5-CN"). In this process, 5-CN is
reacted with 4-fiuorophenylmagnesium halide and N,N-
dimethylaminopropylmagnesium halide to give the corre-
sponding hydroxy intermediate that is then dehydrated with 30
sulfuric acid to give Citalopram.
Although a number of processes have been described for
the preparation of Citalopram, there remains a need in the art
for additional processes that can be prepared in high yield,
at the quality specifications required for use in pharmaceu_ 35
tical applications and without the limitations of the prior art
method disclosed in now expired U.S. Pat. No. 4,136,193.
Quite surprisingly, the present invention fulfills these and
other needs.
4
DETAILED DESCRIPTION OF THE
INVENTION AND PREFERRED
EMBODIMENTS
The present invention provides a process for the prepa-
ration of Citalopram and, in particular, Citalopram.HBr.
FIG. 2 illustrates an exemplary process for the preparation
of Citalopram.HBr in accordance with the present invention.
As illustrated in FIG. 1, the present invention provides a
salt of the compound of Formula III, which can be isolated
as a crystalline material, and a novel, simplified process for
preparing such salt. The ability to isolate a salt of the
compound of Formula III allows one to set the purity at this
step by allowing one to get rid of impurities that would
otherwise be carried through the process, making it impos-
sible to prepare high quality Citalopram.
As such, in one embodiment, the present invention pro-
vides a crystalline salt of the compound of Formula III
having the following structure:
III
OH
Br
F
40
OH
Br
F
In another aspect, the present invention provides a method
for preparing the salt of the compound of Formula III, the
process comprising: (a) contacting a compound of Formula
I having the following structure:
In a presently preferred embodiment, the crystalline salt is
an acid salt. Suitable acid salts include, but are not limited
to, a HCI salt, a HBr salt, a H2S04 salt, a H3 P04 salt, a
methanesulfonic acid salt, a trifiuoroacetic acid salt, an
45
acetic acid salt, a fumaric acid salt and a citric acid salt. In
a presently preferred embodiment, the crystalline salt is an
HCI salt having the following structure:
SUMMARY OF THE INVENTION
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a prior art process used to prepare 55
Citalopram. This process was originally disclosed in now
expired U.S. Pat. No. 4,136,193.
FIG. 2 illustrates a process in accordance with one aspect
of the present invention that can be used to prepare Citalo-
pram in high yield and at the quality specifications required 60
for use in pharmaceutical applications.
FIG. 3 illustrates an example of a feed composition to be
purified.
FIG. 4 illustrates that the product contained in the extract,
i.e., the recovered extract, does not contain any detectable 65
amounts of 5-Br.
FIG. 5 illustrates the recovered raffinate.
The present invention provides a novel process for the
preparation of Citaopram and, in particular, Citalopram.HBr.
Using the process of the present invention, Citalopram.HBr
can be readily prepared in high yields, at the quality speci-
fications required for use in pharmaceutical applications
(i.e., greater than 99.7% pure) and without the limitations of
the prior art methods.
Other features, objects and advantages of the invention 50
and its preferred embodiments will become apparent from
the detailed description which follows.
US 6,967,259 B2
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IV
III
F
Br
5
the method comprising: (a) contacting a salt of the com-
35 pound of Formula III having the following structure:
not limited to, diethylether, t-butylmethylether, THF,
dioxane, toluene, xylene and mixtures thereof. In a preferred
embodiment, the organic solvent used in step (b) is a mixture
of THF and toluene.
In a preferred embodiment, the above method further
comprises: (d) isolating the salt of the compound of Formula
III from the product mixture. In one embodiment, step (d)
comprises: (i) filtering the product mixture to obtain the salt
of the compound of Formula III. In another embodiment,
step (d) further comprises: (ii) washing the salt of the
compound of Formula III with water and toluene. In yet
another embodiment, step (d) further comprises: (iii) recrys-
tallizing the salt of the compound of Formula III from a
member selected from the group consisting of I-butanol,
15 2-butanol and water. In a preferred embodiment, the salt of
the compound of Formula III is recrystallized from
2-butanoI.
In another aspect, the present invention provides a method
for preparing a compound of Formula IV having the fol-
20 lowing structure:
II
Br'CqI 0;
#
o
Br
with 4-fiuorophenyl magnesium bromide to form an inter-
mediate of Formula II having the following structure: 10
F
(b) contacting the intermediate of Formula II with dimethy-
laminopropyl magnesium chloride in an organic solvent to
form a reaction mixture; and (c) quenching the reaction
mixture with an acid to form a product mixture comprising
the salt of the compound of Formula III. In one embodiment 30
of the above process, the crystalline salt is an acid salt.
Suitable acid salts include, but are not limited to, a HCl salt,
a HEr salt, a H2S04 salt, a H3P04 salt, a methanesulfonic
acid salt, a trifiuoroacetic acid salt, an acetic acid salt, a
fumaric acid salt and a citric acid salt. In a presently
preferred embodiment, the crystalline salt is an HCl salt
having the following structure:
OH
OH
Br Br40
45
F
F 50
In connection with this particular embodiment, it has been
surprisingly found that depending on the isolation and
recrystallization procedures used to isolate the HCl salt of
the compound of Formula III, different polymorphs are
obtained. For instance, the crude HCl salt of the compound
of Formula III, isolated from a mixture of THF/toluenel
aqueous HCl has one melting point, whereas the crude HCl
salt of the compound of Formula III recrystallized from
butanol has a second melting point.
As such, in one embodiment, the acid used in step (c) is
a member selected from the group consisting of HCl, HEr,
H2S04 , H3P04 , methanesulfonic acid, trifiuoroacetic acid,
acetic acid, fumaric acid and citric acid. Again, in a preferred
embodiment, the acid is aqueous HCI.
In one embodiment, the solvent used in step (b) is an
organic solvent. Suitable organic solvents include, but are
with about 2 to about 10 equivalents of phosphoric acid to
form a reaction mixture; (b) adding an organic solvent to
said reaction mixture; and (c) quenching said reaction mix-
ture with base to form a product mixture comprising said
55 compound of Formula IV.
With respect to this method, the patent literature (e.g.,
U.S. Pat. No. 4,136,193) teaches that an excess of 60%
phosphoric acid (-30 equivalents) is required in order to
achieve ring closure. However, it has now been surprisingly
60 found that ring closure can be achieved with significantly
fewer equivalents of phosphoric acid (e.g., about 2 to about
10 equivalents). This finding gives rise to a purer product
and numerous other advantages. For instance, one of the
problems associated with the process disclosed in U.S. Pat.
65 No. 4,136,193 for making Citalopram is neutralization of
excess phosphoric acid with ammonia. As expected, this
reaction is very exothermic and takes a long time to neu-
US 6,967,259 B2
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tralize the reaction mixture. Long neutralization time
equates to longer cycle time, which in turn means lower
productivity. Since fewer equivalents of phosphoric acid are
used and the amount of ammonia needed to quench the
5
excess phosphoric acid is reduced, the overall batch size is
higher than the normal batch size by nearly 20%. As such,
the method of the present invention provides purer product,
is more suited for commercial scale production, and has
much higher productivity. 10
IV
F
Br
55
with a mixture of cuprous cyanide and sodium cyanide to
form a reaction mixture; (b) heating the reaction mixture
until the reaction is complete; and (c) quenching the reaction
mixture to form a product mixture comprising the compound
of Formula V. It has been found that a mixture of cyanating
agents works surprisingly well for carrying out this method.
In one embodiment, the compound of Formula IV is in a
first organic solvent. Suitable first organic solvents include,
but are not limited to, toluene, benzene, xylene, diethylether,
t-butylmethylether, dioxane, and mixtures thereof. In a pre-
ferred embodiment, the first organic solvent is toluene. In
25 another embodiment, the mixture of cuprous cyanide and
sodium cyanide is in a second organic solvent. Suitable
second organic solvents include, but are not limited to,
N,N-dimethylformamide, N,N-dimethylacetamide,
N-methylpyrrolidione, quinoline, collidine, xylene,
30 dimethylsulfone, hexamethylphosphoramide and trifiuo-
romethylchlorobenzene. In a preferred embodiment, the
second organic solvent is N,N-dimethylformamide.
It will be readily apparent to those of skill in the art that
the ratio of cuprous cyanide:sodium cyanide in the mixture
35 of cuprous cyanide and sodium cyanide can be varied. In a
presently preferred embodiment, the ratio of cuprous cya-
nide:sodium cyanide in the mixture of cuprous cyanide and
sodium cyanide is about 2.5:1.0 to about 1:2.5. In a presently
preferred embodiment, the ratio of cuprous cyanide:sodium
40 cyanide in the mixture of cuprous cyanide and sodium
cyanide is about 0.50:1.0 to about 2.5:1. In another preferred
embodiment, the ratio of cuprous cyanide:sodium cyanide in
the mixture of cuprous cyanide and sodium cyanide is about
0.75: 1.0 to about 1.0: 1.0. It will be readily apparent to those
45 of skill in the art that other mixtures of cyanating agents
(e.g., KCN:CuCN or Metal-CN:CuCN complexes) can be
used in the above method of the present invention.
In one embodiment, the first organic solvent is removed
from the reaction mixture prior to step (b). In another
50 embodiment, the reaction mixture is quenched with a mem-
ber selected from the group consisting of aqueous sodium
cyanide and aqueous potassium cyanide. In a preferred
embodiment, the reaction mixture is quenched with 10%
aqueous sodium cyanide.
In a preferred embodiment, the above method further
comprises: (d) isolating the compound of Formula V from
the product mixture. In one embodiment, step (d) comprises:
(i) adding ethylenediamine and a first organic solvent to the
reaction mixture and separating the organic phase and the
60 aqueous phase; (ii) re-extracting the aqueous phase with the
first organic solvent; (iii) combining the organic phases to
form a combined organic phase and back-extracting the
combined organic phase with an acid to form an acid extract;
(iv) neutralizing the acid extract with a base to a pH of about
65 8.5 to about 11 to form a neutralized extract; (v) extracting
the neutralized extract with a second organic solvent to form
a second organic solvent extract; (vi) treating the second
v
F
NC
the method comprising: (a) contacting a compound of For-
mula IV having the following structure:
In a preferred embodiment, the above method is carried
out at a temperature of about 80° C.±10° C.
In a preferred embodiment, the above method further
comprises: (c) isolating the compound of Formula IV from
the product mixture. In one embodiment, step (c) comprises:
(i) separating the organic phase and the aqueous phase; (ii)
re-extracting the aqueous phase with toluene; (iii) combin-
ing the organic phases to form a combined organic phase and
washing the combined organic phase with water; and (iv)
distilling the washed organic phase to obtain the compound
of Formula IV.
In another aspect, the present invention provides a method
for preparing a compound of Formula V having the follow-
ing structure:
In another embodiment, the organic solvent in step (b) is
a member selected from the group consisting of toluene,
benzene, xylene, diethylether, t-butylmethylether, dioxane,
and mixtures thereof. In a preferred embodiment, the
organic solvent in step (b) is toluene.
In one embodiment, the salt of the compound of Formula
III is a HCI salt. In another embodiment, the phosphoric acid
is about 20% to about 60% phosphoric acid. In a preferred
embodiment, the compound of Formula III is contacted with 15
about 6 to about 9 equivalents of 20% phosphoric acid. In
another preferred embodiment, the compound of Formula III
is contacted with about 9 equivalents of 20% phosphoric
acid. It will be readily apparent to those of skill in the art that
20
other acids can be used in place of phosphoric acid. Suitable
acids include, but are not limited to, HCI, HEr, sulfuric acid,
trifiuoroacetic acid,and methane sulfonic acid, etc.
In another embodiment, the base is a member selected
from the group consisting of ammonium hydroxide, sodium
hydroxide and potassium hydroxide. In a presently preferred
embodiment, the base is aqueous ammonium hydroxide.
US 6,967,259 B2
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F
F
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the method comprising: (a) dissolving a compound of For-
mula V having the following structure:
in an organic solvent to form a reaction mixture; and (b)
contacting the reaction mixture with HBr to form a product
55 mixture comprising the compound of Formula VI.
In one embodiment, the organic solvent in step (a) is a
member selected from the group consisting of acetone,
methylethylketone, ethylacetate, toluene, benzene, xylene,
diethylether, t-butylmethylether, dioxane, and mixtures
thereof. In a preferred embodiment, the organic solvent in
step (a) is diethylether. In another preferred embodiment, the
organic solvent in step (a) is acetone.
In one embodiment, the HBr is gaseous HBr. In an
example of this embodiment, the method comprises bub-
bling gaseous HBr into the reaction mixture to form a
product mixture comprising the compound of Formula VI.
In another embodiment, the HBr is aqueous HBr and the
isopropanol. Suitable hydrocarbons include, but are not
limited to, heptane, n-heptane, hexane, isohexane, toluene,
cyclohexane, benzene and combinations thereof. Suitable
organic bases include, but are not limited to, triethylamine,
5 diethylamine, trimetylamine, dimethylamine,
tripropylamine, tributylamine, diisopropylethylamine, dicy-
clohexylamine and diethylisopropylamine. In a preferred
embodiment, the organic base is present in the organic
solvent mixture at about 0.05 to about 5%, more preferably
10 at about 0.1 to about 0.5% and, even more preferably, at
about 0.2 to about 0.4%. In a preferred embodiment, the
organic solvent mixture is a mixture of ethanol, heptane and
triethylamine.
In another embodiment, the compound of Formula V is
15 further purified using single column chromatography having
a stationary phase and a mobile phase. It has been found that
single column chromatography works surprisingly well for
removing any non-polar impurities found in the reaction
mixture. Suitable stationary and mobile phases are similar to
20 those described above in connection with the 5MB chroma-
tography.
In another aspect, the present invention provides a method
for preparing a compound of Formula VI having the fol-
lowing structure:
organic solvent extract with charcoal and removing the
second organic solvent to generate the compound of For-
mula V.
In a preferred embodiment of step (d), the first and second
organic solvents are independently selected from the group
consisting of toluene, benzene, xylene, diethylether,
t-butylmethylether, dioxane, and mixtures thereof. In
another preferred embodiment, the first and second organic
solvents are both toluene.
In one embodiment, the acid in step (iii) is a member
selected from the group consisting of HCl, HBr, H2S04 ,
H3 PO4' trifiuoroacetic acid and acetic acid. In a preferred
embodiment, the acid in step (iii) is 20% aqueous acetic
acid. In one embodiment, the base in step (iv) is a member
selected from the group consisting of sodium hydroxide,
potassium hydroxide and sodium carbonate. In a preferred
embodiment, the base in step (iv) is sodium hydroxide. In
one embodiment, the acid extract in step (iv) is neutralized
with the base to a pH of about 9 to about 10.
In another aspect, the above method further comprises
purifying the compound of Formula V using simulated
moving bed (SMB) chromatography having a stationary
phase and a mobile phase. It has been found that 5MB
chromatography works surprisingly well for removing non-
polar impurities found in the reaction mixture. In one 25
embodiment, the stationary phase is a reverse phase silica
gel and the mobile phase is an organic solvent/water mix-
ture. A C18-derivatized silica gel is an example of a suitable
reverse phase silica gel. Typically, the pH of the mobile
phase is about 1.5 to about 4.0, more preferably about 2.5. 30
The pH of the mobile phase can be maintained by, for
example, the addition of 0.1 to 2% trifiuoroacetic acid. In a
preferred embodiment, the organic solvent in the mobile
phase is methanol. In another preferred embodiment, the
organic solvent in the mobile phase is ethanol. In another 35
preferred embodiment, the organic solvent in the mobile
phase is acetonitrile.
In another embodiment, the stationary phase is a normal
phase silica gel and the mobile phase is an organic solvent
mixture. In one embodiment, the organic solvent mixture is 40
a mixture of an alcohol, a hydrocarbon and an organic base.
Suitable alcohols include, but are not limited to, methanol,
ethanol, n-propanol and isopropanol. Suitable hydrocarbons
include, but are not limited to, heptane, n-heptane, hexane,
isohexane, toluene, cyclohexane, benzene and combinations 45
thereof. Suitable organic bases include, but are not limited
to, trie th ylamine, die thy lamine, trime ty lamine,
dimethylamine, tripropylamine, tributylamine,
diisopropylethylamine, dicyclohexylamine and diethyliso-
propylamine. In a preferred embodiment, the organic base is 50
present in the organic solvent mixture at about 0.05 to about
5%, more preferably at about 0.1 to about 0.5% and, even
more preferably, at about 0.2 to about 0.4%. In a preferred
embodiment, the organic solvent mixture is a mixture of
ethanol, heptane and triethylamine.
In another embodiment, the stationary phase is a chiral
phase silica gel and the mobile phase is an organic solvent
mixture. Suitable chiral phase silica gel stationary phases
include, but are not limited to, CHIRALPAK® ADTM;
CHIRALPAK® ASTM; CHIRALCEL® ODTM; and 60
CHIRALCEL® OFM, all of which are commercially avail-
able from Daicel, through its subsidiary, Chiral Technolo-
gies Inc. In one embodiment, the organic solvent mixture is
a mixture of an alcohol (which mayor may not be denatured
with, for example, a hydrocarbon such as n-heptane), a 65
hydrocarbon and an organic base. Suitable alcohols include,
but are not limited to, methanol, ethanol, n-propanol and
US 6,967,259 B2
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wherein: R is a functional group that is reactive with a
primary and/or secondary amine such as those described
above.
The above method is typically carried out by stirring a
crude Citalopram mixture containing A and/or B in an
appropriate solvent with a scavenger resin having a func-
tional group that is reactive with the primary and/or sec-
40 ondary amine functionalities present in A and B, respec-
tively. Suitable solvents include, but are not limited to,
toluene, benzene, xylene, diethylether, t-butylmethylether,
dioxane, and mixtures thereof. The resulting mixture is a
heterogeneous mixture as the scavenger resin is also
45 insoluble in the solvent. It is thought that impurities A and
B, but not Citalopram, attach to the resin by making a
covalent bond between a primary or secondary amine func-
tionality and the functional group on the scavenger resin,
thereby rendering them insoluble. A simple filtration of the
50 resin-bound, i.e., insoluble, impurities A and B affords a
purified Citalopram solution virtually free of impurities A
and B.
The above method has a number of significant advantages
including, but not limited to, the following: (1) it selectively
55 renders otherwise soluble impurities A and B insoluble by
binding them to the insoluble resin through the reaction of
the reactive end groups of the scavenger resin and the
primary and secondary amine functionalities present in
impurities A and B; (2) the scavenger resin will bind any
other impurity containing a primary or secondary amine
60 functionalities and render them insoluble as well; (3) the
scavenger resin cannot react with the desired Citalopram,
which has a tertiary amine functionality; (4) once the resin
binds to the impurities A, B (or any other impurity contain-
ing a primary or secondary amine functionality) rendering
65 them insoluble, only a simple filtration is required to remove
these impurities, thereby minimizing any loss (i.e., any loss
due to the acid/base wash and/or crystallization and recrys-
primary or secondary amine to form resin-bound demethyl-
and/or didemethyl-impurities, wherein the scavenger resin is
insoluble in the solvent; and (b) filtering the resin-bound
demethyl- and/or didemethyl-impurities, thereby removing
5 the demethyl and/or didemethyl-impurities from the mixture
of Citalopram.
In one embodiment of the above method, the functional
group on the scavenger resin includes, but is not limited to,
isocyanates, isothiocyanates, acid chlorides, esters and
anhydrides. In some embodiment, the scavenger resin can
10 have more than one functional group and, in this case, the
functional groups can be the same or different. It has been
found that such functional groups react with the primary
and/or secondary amine functionalities present in impurities
A and B, virtually in an irreversible fashion, thereby attach-
15 ing impurities A and B to the scavenger resin. The attach-
ment of impurities A and B to the scavenger resin renders
such impurities insoluble as well.
The scavenger resin can be any resin that (1) is insoluble
in the solvent in which the product is dissolved; (2) is
20 non-reactive with the solvent in which the product is dis-
solved; and (3) contains a functional group that is reactive
with a primary and/or a secondary amine. In one
embodiment, the scavenger resin is a polystyrene-based
resin. In another embodiment, the scavenger resin is a silica
25 gel-based resin. In a preferred embodiment, the scavenger
resin is a polystyrene-based resin having the following
structure:
F
NC
reaction mixture is contacted with aqueous HBr to form a
product mixture comprising the compound of Formula VI.
In a preferred embodiment, the above method further
comprises: (c) isolating the compound of Formula VI from
the product mixture. In one embodiment, step (c) comprises:
(i) cooling the product mixture and filtering the product
mixture to obtain the compound of Formula VI as a pre-
cipitated solid; (ii) washing the precipitated solid with an
organic solvent; and (iii) drying the precipitated solid to
obtain the compound of Formula VI. In one embodiment,
step (c) further comprises: (iv) recrystallizing the compound
of Formula VI. In one embodiment, the compound of
Formula VI is recrystallized from a solvent mixture of
toluene and methanol. In another embodiment, the com-
pound of Formula VI is recrystallized from a solvent mixture
of methanol and isopropylalcohol (IPA).
In another embodiment, step (iv) comprises: (i') combin-
ing the precipitated solid with toluene and methanol to form
a mixture and heating the mixture; (ii') filtering the mixture
through Celite and slowly cooling the mixture; and (iii')
filtering the mixture to obtain the crystallized solid, washing
the crystallized solid with toluene, and drying the crystal-
lized solid to obtain the compound of Formula VI. In one
embodiment, in step (ii'), the mixture is cooled to about
ambient temperature. In another embodiment, in step (ii'),
the mixture is cooled to about 0° C. to about 5° C.
In yet another embodiment, step (iv) comprises: (i')
combining the precipitated solid with methanol and isopro-
pylalcohol (IPA) to form a mixture and heating the mixture;
(ii') filtering the mixture through Celite and slowly cooling
the mixture; and (iii') filtering the mixture to obtain the 30
crystallized solid, washing the crystallized solid with
isopropylalcohol, and drying the crystallized solid to obtain
the compound of Formula VI. In one embodiment, in step
(ii'), the mixture is cooled to about ambient temperature. In
another embodiment, in step (ii'), the mixture is cooled to
about 0° C. to about 5° C. 35
In another embodiment, the present invention provides a
process for the removal of demethyl-(A) and didemethyl-(B)
impurities from crude Citalopram mixtures, wherein the
demethyl- and didemethyl-impurities have the following
structures:
Demethyl-(A) and didemethyl-(B) impurities are common
impurities formed at various stages during the preparation of
Citalopram. Unfortunately, these troublesome impurities
present a challenge in removal due to their structural prox-
imity to Citalopram.
As such, the present invention provides a method for
removing demethyl- and didemethyl-impurities from a
crude Citalopram mixture containing demethyl- and
didemethyl-impurities in a solvent, the method comprising:
(a) contacting the mixture of Citalopram with a scavenger
resin having a functional group that is reactive with a
US 6,967,259 B2
C. Purification of Bromodiol HCl
A mixture of crude bromodiol*HCl (1.60 kg) and 65
2-butanol (8.00 kg) was heated to 70° C. to form a hazy
solution and filtered through a bed of celite.
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tallization utilized in the method disclosed in PCT Patent
Publication No. WO 01/45483 A2); and (5) once the filtra-
tion is performed, a purified Citalopram solution is obtained
and the purified Citalopram can be recovered by a simple
evaporation of the solvent. 5
The invention will be described in greater detail by way
of specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the
invention in any manner. Those of skill in the art will readily
recognize a variety of non-critical parameters which can be 10
changed or modified to yield essentially the same results.
F. Process for the Preparation of 5-Cyano-1-(3-
dimethylaminopropyl)-l-(p-fluorophenyl)phthalane
(" Citalopram"or "5-CN")
A solution of 5-bromo-1-(3-dimethylaminopropyl)1-(p-
fluorophenyl)phthalane (100.5 g, 0.266 mol) in toluene
was added to a mixture of cuprous cyanide (50.0 g,
0.558 mol) and sodium cyanide (9.8 g, 0.200 mol) in of
N,N-dimethylformamide (450 mL)
14
The resulting solution was cooled slowly to 5° C. to
precipitate the product.
The resulting slurry was filtered and washed with
2-butanol (1.60 kg).
The off-white solids were dried at 35-40° C. under
vacuum to yield 1.18 kg (73.8% recovery from crude)
of bromodiol*HCl.
The properties of the Bromodiol*HCl are as follows:
HPLC area % purity: 99.9%.
mp (DSC): 183° C.
lH NMR (d-DMSO): 010.19 (s, lH), 07.0-7.8 (m, 7H),
05.90 (s, lH), 05.17 (s, lH), 04.49 (d, lH), 03.97 (d, lH),
03.02 (m, 2H), 02.65 (s, 6H), 02.21 (m, 2H), 01.65 (m, lH),
01.36 (m, lH).
E. Modified Process for the Preparation of 5-Br
A mixture of bromodiol*HCl (0.200 kg, 0.462 mol, 1.00
eq.) and 20% phosphoric acid (2.04 kg, 4.16 mol, 9.00
eq.) was heated to 90° C. for 2.5 h.
The mixture was cooled to <10° C.
Toluene (1.20 kg) was added to the solution and the
mixture was quenched with 28% aqueous ammonium
hydroxide (0.574 kg, 4.59 mol, 9.93 eq.), maintaining
<25° C.
The phases were separated and the aqueous layer was
re-extracted with toluene (0.800 kg).
The organic phases were combined and washed with
water (0.800 kg).
The solvent was distilled from the washed organic
extracts to yield 164 g (93.6% yield) of 5-Br as an
orange oil.
The properties of 5-Br are as follows:
HPLC area % purity: 99.2%.
lH NMR (d-DMSO): 07.1-7.6 (m, 7H), 05.10 (m, 2H),
02.51 (m, 2H), 02.11 (m, 2H), 02.01 (s, 6H), 01.23 (m, 2H).
D. Preparation of 5-Bromo-1-(4-fluorophenyl)-1-(3-
dimethylaminopropyl)-phthalan (,,5-Br")
A mixture ofbromodiol*HCl (1.12 kg, 2.59 mol, 1.00 eq.)
and 60% phosphoric acid (12.7 kg, 77.8 mol, 30.0 eq.)
was heated to 90° C. for 1 h.
The mixture was cooled to <10° C.
Toluene (6.72 kg) and water (8.96 kg) were added to the
solution and the mixture was quenched with 28%
aqueous ammonium hydroxide (9.37 kg, 74.9 mol, 28.9
eq.), maintaining <25° C.
The phases were separated and the aqueous layer was
re-extracted with toluene (4.48 kg).
The organic phases were combined and washed with
water (4.0 kg).
The solvent was distilled from the washed organic
extracts to yield 977 g (99.2% yield, 95.2% yield
corrected for residual solvents) of 5-Br as an orange oil.
The properties of 5-Br are as follows:
HPLC area % purity: 99.0%.
lH NMR (d-DMSO): 07.1-7.6 (m, 7H), 05.10 (m, 2H),
02.51 (m, 2H), 02.11 (m, 2H), 02.01 (s, 6H), 01.23 (m, 2H).
55
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EXAMPLES
A. Preparation of Dimetlylaminopropyl Magnesium
Chloride
A solution of 1.1 M 4-fluorophenyl magnesium bromide
in THF (5.57 kg, 6.01 mol, 1.28 eq.) was added to a 45
mixture of 5-bromophthalide (1.00 kg, 4.69 mol, 1.00
eq), and toluene (6.25 kg) at <20° C. over 1 h.
The mixture was stirred at <20° C. for 0.5 h.
A solution of 1.8 M dimethylaminopropyl magnesium
chloride (3.90 kg, 7.02 mol, 1.50 eq.) was added to the 50
mixture over 2 h, maintaining <30° C. with cooling.
The resulting mixture was stirred ambient temperature for
16 h.
The mixture was quenched into 6.23% aqueous hydro-
chloric acid (9.9 kg, 19.3 mol, 4.1 eq.).
The slurry was stirred at ambient temperature for 1 hand
filtered.
The product was then washed with water (2.00 kg) and
toluene (4.00 kg).
The off-white solids were dried at 35-40° C. under 60
vacuum to yield 1.63 kg (80.4% yield) of crude
bromodiol*HCl.
A 30% aqueous sodium hydroxide (1.04 kg, 7.80 mol,
1.10 eq.) solution was added to a mixture of 65%
aqueous dimethylaminopropyl chloride hydrochloride
(1.71 kg, 7.04 mol, 1.00 eq.) and toluene (0.167 kg) at 20
<20° C.
The phases were separated.
The organic phase was combined with THF (0.600 kg)
and dried over molecular sieves (Siliporite NKlO,
0.227 kg). 25
Approximately 5% of the dried dimethylaminopropyl
chloride solution was added to a mixture of magnesium
(0.170 kg, 7.00 mol, 1.00 eq.), ethyl bromide (0.0038
kg, 0.035 mol, 0.0050 eq.), and THF (1.60 kg).
30The resulting mixture was heated to reflux (>68° C.) and
the remaining dimethylaminopropyl chloride solution
was added over 1.5 h.
Reflux (>68° C.) was maintained throughout the addition
period by adjusting the addition rate and heating and/or
cooling as necessary. 35
The mixture was refluxed (>70° C.) for 1 h, then cooled
to ambient temperature and stored under a dry nitrogen
atmosphere.
B. Preparation of (4-Bromo-2-hydroxymethyl) 40
phenyl-(4-fluoropheny1)-(3-dimethylaminopropy1)
Methanol Hydrochloride
US 6,967,259 B2
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Toluene was removed by distillation and the resulting
mixture was heated to 154-159° C. under nitrogen until
the desired conversion was achieved.
The reaction mixture was then chilled to 60-70° C. and
quenched with a 10% aqueous NaCN solution (350 g). 5
Aqueous ethylenediamine (41% solution, 140 g) and
toluene (500 mL) were added and the mixture was
filtered.
The organic layer was separated and the aqueous layer 10
was extracted with toluene (2x100 mL).
The combined organic extracts were washed with water
(2x100 mL).
The organic extract was then extracted with 20% acetic
acid solution (2x250 mL). 15
The combined acetic acid extracts were neutralized with
16.6% aqueous NaOH to a pH of about 9 to about 10
and extracted with toluene (3x300 mL).
The combined toluene extracts were treated with activated
charcoal (16.1 g) and stripped of solvent under reduced 20
pressure to give crude Citalopram (72.3 g, 84%) as a
light brown oil.
The properties of 5-CN are as follows:
HPLC purity: 95% with 5% unreacted 5-Br.
lH NMR (DMSO-d6): 07.6 (s, 1H, 4-H aromatic proton), 25
6.98 to 7.52 (m, 6H, aromatic protons), 5.25 (d, 1H, 3-HJ,
5.15 (d, lH, 3-Hb ), 3.08 (t, 2H, 3'-CH2), 2.71 (s, 6H,
-N(CH3)2)' 2.49 to 2.27 (m, 2H, l'-CH2), 1.82 to 1.71 (m,
2H, 2'-CH2);
LC/MS: m/z, 325 (M+1). 30
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The properties of Citalopram-HBr are as follows:
mp (DSC): 186° C.
HPLC Purity: 99.8%.
IR(~0:2931,2655,2229,1507,1217,1028,1013,835
cm-\
lH NMR (DMSO-d6): 09.15 (s, lH, -NH(CH3)2), 7.71
to 7.91 (m, 3H, aromatic protons), 7.52 to 7.64 (m, 2H,
aromatic protons), 7.06 to 7.27 (m, 2H, aromatic protons),
5.08 to 5.28 (q, 2H, 3-H), 3.3 (t, 2H, 3'-CH2), 2.65 (s, 6H,
-NH(CH3)2), 2.2 (t, 2H, l'-CH2), 1.29 to 1.60 (m, 2H,
2'-CH2)·
J. Process for the Preparation of 5-Cyano-1-(3-
dimethylaminopropyl)-l-(p-fiuorophenyl)phthalane
HBr (Citalopram-HBr)
In addition to the foregoing method, Citalopram.HBr can
be prepared using aqueous HBr. It has been found that the
resulting product prepared using aqueous HBr is equivalent
to that prepared using gaseous HBr in both yield and purity.
C.HBr Salt Formation
48% HBr (aq) (54.1 g, 0.321 mol) is added to a stirred
solution of 5-CN (104.1 g, 0.31 mol) in Toluene (366
g) at 5-10° C.
The resulting slurry is cooled to 0-5° C. and filtered.
The product is washed with cold Toluene (2x107 mL) and
dried in vacuo (60-80° C. at 5-10 mm Hg) to afford
C-HBr (97.5 g, 93.6%) as a white solid.
Recrystallization/Purification
A mixture of C-HBr (97.5 g, 0.301 mol), methanol (103.6
g) and isopropanol (207.2 g) is heated to 60-70° C.
The resulting solution was cooled to 0° C. and filtered.
The recrystallized product was washed with cold isopro-
panol (2x75 mL) and dried in vacuo (60-80° C. at 5-10
mm Hg) to afford C-HBr (88.6 g, 85.1%) as a white
solid.
The properties/characterization of pure C-HBr are as
45 follows:
A recrystallization is not necessary when using 5-CN
purified by 5MB chromatography. However, the following
35 can be performed if further purification is required or
desired.
G. Process for the Purification of Crude 5-CN
H. Process for the Preparation of 5-Cyano-1-(3-
dimethlylaminopropyl)-l-(p-fiuorophenyl)phthalane
HBr (Citalopram-HBr)
The crude 5-CN product is dissolved in a mixture of
heptane/ethanoIITEA(90%:1O%:0.1%), and separated using
Multi-Column Chromatography (MCC) equipment (SMB)
to provide 5-CN with <0.1% 5-Br. The mobile phase is
heptane/ethanoIITFA. The stationary phase is CHIRALCEL
ODTM. MCC separation has been demonstrated on 400 g
scale and the product isolated from the separation was 40
>99.9% pure. The product was so pure that when it was
converted to the HBr salt, it maintained its purity and did not
require additional purification-a 20% savings in the yield.
1870 C.
99.8%
None detected
~0.2%
None detected
2931, 2655, 2229, 1507, 1217, 1028,
1013, 835 cm-';
09.15 (s, lH, -NH(CH3hl, 7.71 to 7.91
(m, 3H, aromatic protons), 7.52 to 7.64
(m, 2H, aromatic protons), 7.06 to 7.27
(m, 2H, aromatic protons), 5.08 to 5.28
(q, 2H, 3-H), 3.3 (t, 2H, 3'-CH2),
2.65 (s, 6H, -NH(CI:h)2), 2.2 (t, 2H,
l'-CH2), 1.29 to 1.60 (m, 2H, 2'-CH2).
K. Removal of Demethyl and Didemethyl
Impurites from a Crude Citalopram Mixture
Methylisocyanate polystyrene resin (0.34 g, 0.18 mol
isocyanate) is added to a solution of 5-CN (0.92 g) in
Toluene (10 g) and stirred at room temperature.
'H NMR (OMSO-do):
mp (ose):
HPLC Purity:
50 5-Br:
Total Impurities:
Unknown Inpurities ~0.1%:
IR(KBr):
I. Purification of Citalopram-HBr
A mixture of the crude product (69.8 g), toluene (1117 g), 60
and methanol (138 g) was heated to 60-70° C.
The resulting solution was filtered through celite and
slowly cooled to ambient temperature.
The crystallized solid was filtered, washed with 100 mL
toluene, and dried in vacuo (60-80° C. at 10 mmHg) to 65
give pure Citalopram-HBr (53.2 g, 76.2%), a white
solid.
HBr gas (18.0 g, 0.223 mol) was bubbled into a stirred
solution of pure 5-CN (72.3 g, 0.223 mol) in 723 mL
acetone at 20-25° C.
The resulting slurry was cooled to 0-5° C. and filtered.
The product was washed with cold acetone (3x100 mL)
and dried in vacuo (60-80° C. at 5-10 mmHg) to give 55
Citalopram-HBr (69.8 g, 77.3%), a white solid.
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Product Recovery
What is claimed is:
1. A method for preparing a salt of the
Formula III having the following structure:
[Let's discuss whether or not to include the loading study
as well as the other information in the discussion section]
The expected quantity of 5-CN to be recovered was
641.5-g. The total extract collected was 576.2-g representing
a recovery yield of 89.8%.
The solvent recovered was sampled and tested and accept-
able low amount of product was detected (traces).
Based on these experimental data, the production rate for
the separation is 1.31-kg/d of 5-CN at 17 bars. This corre-
sponds to a productivity of 1.49 kg of Citalopram per day per
kg of CSP at 17 bars (free of 5-Br).
The total quantity of product recovered is 675.3-g (all
fractions included), which gives an overall yield for the
process of 96%. The 4% loss is due to product loss in the
equipment (tanks walls, tubing, 5MB unit) and when recov-
ering the fractions.
The product obtained in the extract does not contain
detectable amount of 5-Br (see, FIGS. 4 and 5).
It is understood that the examples and embodiments
described herein are for illustrative purposes only and that
various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included
within the spirit and purview of this application and scope of
the appended claims. All publications, patents, and patent
applications cited herein are hereby incorporated by refer-
ence for all purposes.
A sample of each recovered fraction was analyzed using
a C18 column (reverse phase) and a gradient of water with
TFA (trifluoroaceticacid) and acetonitrile with TFA.
The raffinate was re-dissolved in a small amount of
ethanol denatured and evaporated in a 1-L flask using the
laboratory evaporator (Buchii). The raffinate product (5-Br)
was recovered as a viscous oil.
Separation Performance
Each recovered fraction (extract and raffinate) was evapo-
rated in 20-L rotary evaporators (Genser, Germany). The
5 Extract fraction was evaporated to dryness and the product
was recovered as a crystal. The evaporation step was con-
ducted at 40-° C. (waster bath) and under vacuum (150-mbar
to start the process and down to 80-mbar for drying the
product) with 50-rpm for the flask speed.
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After 2 h at room temperature, the resin was filtered and
Toluene was evaporated in vacuo (50-60° C. at 5-10
mm Hg) to afford product with 70% less demethyl
impurity (A).
L. 5MB Purification of Citalopram-HBr
Experimental
The feed mixture is an oil recovered from the cyanation
step and contains several impurities (polar and non-polar).
These impurities can mostly be removed by standard 10
reworking of the product (e.g., by crystallization and solvent
exchange). However, one impurity is not removed by these
techniques. This impurity is the starting material of the
previous step. It is the 5-Br intermediate that is converted
into Citalopram during the cyanation step. 15
The separation of a mixture of Citalopram and 5-Br
intermediate in the proportion 95/5 (HPLC area % at 232-
nm) was examined by chromatography and more specifi-
cally by the simulated moving bed technique. FIG. 3 20
(reverse phase analysis) gives an example of the feed
composition. The largest peak is the Citalopram peak. The
second largest peak is the 5-Br intermediate. The other peaks
are of lesser interest for the chromatographic separation.
The following equipment was used for the experiment. 25
5MB unit: Licosep laboratory unit from NOVASEP
(Brabois (54), France) equipped with 8 axial compression
columns from MERCK (Darmstadt, Germany). Each col-
umn was 50-mm internal diameter and was prepared using
110-g of CHIRALCEL ODTM 20-,um chiral stationary phase 30
(Chiral Technologies Inc, Exton, USA). The average column
length was 1O.3-cm. The mobile phase used for the separa-
tion was a mixture of ethanol (denatured with n-heptane)
and n-heptane in the proportion 10/90% (v/v.). Triethy-
lamine was added as a modifier (0.2% total volume). The 35
separation was conducted at 30° C. Under such conditions,
the compound of interest (Citalopram) is the second eluting
compound and will be designed as the Extract, 5-Br will be
the Raffinate.
Each column was individually tested with a diluted solu- 40
tion of the mixture to be separated (14.2-gll). The injected
volume was O.5-ml. Detection was performed at 254-nm and
the flow rate was 100-mllmin. The 5-Br average elution time
is 1.92-min while the Citalopram has an averaged elution
time of 3.1O-min. The average to (or dead volume) of the
45
column was 1.51-min. The average retention factor for the
5-Br was 0.27 and was 1.04 for the Citalopram. The average
selectivity of the separation was 3.84.
Separation Parameters
The separation was conducted using 703.1 g of a mixture 50
of Citalopram and 5-Br prepared according to the cyanation
procedure. The feed composition is 95% of Citalopram and
5% of 5-Br (area % by HPLC at 232-nm). The feed contains
other impurities, but they were not taken into account in the
calculation of the feed composition. The feed concentration 55
for this step was 22.7-gll.
The set of parameters used for the separation was:
Zone I
Period Eluent (recycle) Extract Zone II Feed Zone III Raffinate Zone IV
min ml/min ml/min ml/min ml/min ml/min ml/min ml/min ml/min
1.65 86.7 190 76.7 113.3 40@ 153.3 50 103.3
22.7 gil
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with 4-fiuorophenyl magnesium bromide to form an inter-
mediate of Formula II having the following structure:
said method comprising:
(a) contacting a compound of Formula I having the
following structure:
5
25
(b)contacting said intermediate of Formula II with dim-
ethylaminopropyl magnesium chloride in an organic
solvent to form a reaction mixture; and
(c) quenching said reaction mixture with an acid to form
a product mixture comprising said salt of the compound
of Formula III.
2. The method of claim 1, wherein said salt of the
compound of Formula II is an acid salt.
3. The method of claim 2, wherein said acid salt is a
member selected from the group consisting of a HCI salt, a
10 HEr salt, a H2S04 salt, a H3P04 salt, a methanesulfonic acid
salt, a trifiuoroacetic acid salt, an acetic acid salt, a fumaric
acid salt and a citric acid salt.
4. The method of claim 1, wherein said organic solvent in
step (b) is a member selected from the group consisting of
15 diethylether, t-butylmethylether, THF, dioxane, toluene,
xylene and mixtures thereof.
5. The method of claim 1, wherein said organic solvent in
step (b) is a mixture of THF and toluene.
6. The method of claim 1, wherein said acid in step (c) is
20 a member selected from the group consisting of HCI, HEr,
H2S04 , H3 P04 , methanesulfonic acid, trifiuoroacetic acid,
acetic acid, fuinaric acid and citric acid.
7. The method of claim 1, wherein said acid is aqueous
HCI.
8. The method of claim 1 further comprising:
(d) isolating said salt of the compound of Formula III
from said product mixture.
9. The method of claim 8, wherein step (d) comprises:
(i) filtering said product mixture to obtain said salt of the
compound of Formula III.
10. The method of claim 9, wherein step (d) further
comprises:
(ii) washing said salt of the compound of Fonnula III with
water and toluene.
35 11. The method of claim 10, wherein step (d) further
comprises:
(iii) recrystallizing said salt of the compound of Formula
III from a member selected from the group consisting
of I-butanol, 2-butanol and water.
40 12. The method of claim 11, wherein step (d) further
comprises:
(iv) recrystallizing said salt of the compound of Formula
III from 2-butanoI.
30
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